Home › Chronic Myeloid Leukemia
Pag-aaral pangklinika para sa Chronic Myeloid Leukemia na nagre-recruit sa U.S.
48 pag-aaral para sa Chronic Myeloid Leukemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX18 pag-aaral
- Seattle, WA11 pag-aaral
- New York City, NY11 pag-aaral
- Detroit, MI6 pag-aaral
- Birmingham, AL6 pag-aaral
- Philadelphia, PA6 pag-aaral
- Chicago, IL6 pag-aaral
- Baldwin Park, CA6 pag-aaral
- Portland, OR6 pag-aaral
- Nashville, TN5 pag-aaral
- Columbus, OH5 pag-aaral
- Milwaukee, WI5 pag-aaral
- Baltimore, MD5 pag-aaral
- Atlanta, GA5 pag-aaral
- Boston, MA5 pag-aaral
- Durham, NC5 pag-aaral
- Rochester, NY4 pag-aaral
- Mountain View, CA4 pag-aaral
- Cincinnati, OH4 pag-aaral
- Kansas City, MO4 pag-aaral
- Augusta, GA4 pag-aaral
- Washington, DC4 pag-aaral
- St. Louis, MO4 pag-aaral
- Sacramento, CA3 pag-aaral
- Edison, NJ3 pag-aaral
- Salt Lake City, UT3 pag-aaral
- Cleveland, OH3 pag-aaral
- Orange, CA3 pag-aaral
- Miami, FL3 pag-aaral
- Bridgeport, CT3 pag-aaral
- Buffalo, NY3 pag-aaral
- Ann Arbor, MI3 pag-aaral
- Aurora, CO3 pag-aaral
- St. Petersburg, FL3 pag-aaral
- Greenville, NC3 pag-aaral
- Minneapolis, MN3 pag-aaral
Ayos sa estado
- Alabama6 pag-aaral
- Arizona4 pag-aaral
- California10 pag-aaral
- Colorado4 pag-aaral
- District of Columbia3 pag-aaral
- Florida7 pag-aaral
- Georgia7 pag-aaral
- Illinois6 pag-aaral
- Indiana3 pag-aaral
- Kansas5 pag-aaral
- Kentucky3 pag-aaral
- Maryland6 pag-aaral
- Massachusetts5 pag-aaral
- Michigan7 pag-aaral
- Minnesota4 pag-aaral
- Missouri4 pag-aaral
- Nebraska3 pag-aaral
- New Jersey4 pag-aaral
- New York15 pag-aaral
- North Carolina8 pag-aaral
- Ohio9 pag-aaral
- Oregon6 pag-aaral
- Pennsylvania7 pag-aaral
- Tennessee5 pag-aaral
- Texas18 pag-aaral
- Utah3 pag-aaral
- Virginia4 pag-aaral
- Washington11 pag-aaral
- Wisconsin5 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06904066Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06817720Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Nagre-recruitPhase 1/2
Edad 1 hanggang 17 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04925479Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07269470Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06236724Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06398457Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Nagre-recruitPhase 1
Edad 1 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT03630991Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06423911Cord Blood Transplant in Adults With Blood Cancers
Nagre-recruitPhase 2
Edad 21 hanggang 65 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05884333Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Nagre-recruitPhase 2
Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07354074Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT06523556Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Nagre-recruitPhase 1
1 Day – 21 Years · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT05857969Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04838041TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Nagre-recruitPhase 1
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07302776Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Nagre-recruitPhase 2
6 Months – 65 Years · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06013423A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545Allo HSCT Using RIC and PTCy for Hematological Diseases
Nagre-recruitPhase 2
Hanggang edad 75 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT05805605Asciminib Roll-over Study
Nagre-recruitPhase 4
Edad 7 hanggang 100 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04877522Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Nagre-recruitPhase 2
Hanggang edad 60 · Lahat ng kasarian · Na-update Hun 25, 2026 · NCT03314974Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT05549661Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT07638007Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.